Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ampicillin-sulbactam + fluconazole
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
A combination of ampicillin-sulbactam, an antibiotic consisting of ampicillin (a penicillin-class antibiotic) and sulbactam (a beta-lactamase inhibitor), with fluconazole, a triazole antifungal medication. This combination may be used in treating mixed bacterial and fungal infections, though there are concerns about potential antagonistic interactions between these medications.
- Brand names
- Unasyn + Diflucan
02
Targets
β-lactamasePBP (Penicillin-binding protein family)CYP51A1 (Sterol 14α-demethylase)
Beyond the preview
Go deeper on ampicillin-sulbactam + fluconazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ampicillin-sulbactam + fluconazole.